findmyKOL
Clinical trialNCT05174455WithdrawnPhase 2Interventional

Niraparib for the Treatment of Leiomyosarcoma

SponsorDavid Liebner, MDEnrollment0Locally Advanced LeiomyosarcomaMetastatic LeiomyosarcomaStage III Retroperitoneal Sarcoma AJCC v8Stage IIIA Retroperitoneal Sarcoma AJCC v8Stage IIIB Retroperitoneal Sarcoma AJCC v8Stage IV Retroperitoneal Sarcoma AJCC v8+1 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial tests whether niraparib works to shrink tumor in patients with leiomyosarcoma. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • David Liebner, MD

    Ohio State University Comprehensive Cancer Center

    Principal Investigator
    clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Niraparib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Dec 2023
Primary completion
31 Dec 2024
Completion
31 Dec 2025
Last update posted
18 Sept 2023
Registered enrollment
0
Registry id
NCT05174455
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.